Assembly Biosciences (ASMB)
NASDAQ:ASMB
Want to see ASMB full AI Analyst Report?
ASMB Stock Chart & Stats
$29.24
-$0.45(-2.59%)
At close: 4:00 PM EST
$29.24
-$0.45(-2.59%)
Day’s Range― - ―
52-Week Range$15.12 - $39.71
Previous CloseN/A
Volume7.37K
Average Volume (3M)164.41K
Market Cap
$471.46M
Enterprise Value$410.96M
Total Cash (Recent Filing)$226.60M
Total Debt (Recent Filing)$2.49M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 12, 2026EPS Estimate
-0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding19,251,210
10 Day Avg. Volume178,321
30 Day Avg. Volume164,409
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)1.84
Price to Sales (P/S)5.27
P/FCF Ratio-9.26
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue5.78
Enterprise Value/Gross Profit7.48
Enterprise Value/Ebitda-34.93
Forecast
1Y Price Target
$44.33Price Target Upside51.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.81
Revenue Forecast (FY)$58.29M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetExtremely low debt and sizable equity give durable financial flexibility to fund clinical programs and absorb operating losses. A conservative capital structure reduces bankruptcy risk, supports partnering or licensing options, and preserves optionality across 2–6 month development milestones.
Material Equity Financing Bolstering RunwayThe $107.4M net proceeds materially extend cash runway, lowering near-term refinancing risk and enabling planned Phase 2 starts. Institutional participation (including healthcare-focused investors) signals continued external support, improving probability of executing clinical development plans.
Pipeline Expansion: ABI-6250 Into Cholestatic DiseasesBroadening ABI-6250 into PBC and PSC diversifies the company’s addressable market beyond HDV, targeting high unmet need and potentially creating multiple Phase 2 readouts. A mechanistically distinct oral NTCP approach could offer differentiation if safety and efficacy are confirmed.
Bears Say
Sustained Cash Burn / Negative Operating Cash FlowPersistent negative operating and free cash flow indicates the business consumes material cash to progress trials. Continued burn necessitates further funding unless milestones rapidly de-risk programs, increasing reliance on equity or partnership funding and pressuring long-term self-sustainability.
Volatile, Declining Revenue And Ongoing LossesSharp revenue decline and sustained net losses reduce predictability of financial performance. Negative margins and ROE compress internal funding capacity, make planning for sequential clinical programs harder, and increase dependence on external capital or milestone-based partnerships.
Dilution Risk From Recent Equity And Warrant IssuanceThe recent offering and exercisable pre-funded warrants dilute existing holders and can expand share count if exercised. While proceeds aid development, dilution is a lasting structural change to per-share economics and could affect governance and long-term returns absent offsetting value creation.
Assembly Biosciences News
ASMB FAQ
What was Assembly Biosciences’s price range in the past 12 months?
Assembly Biosciences lowest stock price was $15.12 and its highest was $39.70 in the past 12 months.
What is Assembly Biosciences’s market cap?
Assembly Biosciences’s market cap is $471.46M.
When is Assembly Biosciences’s upcoming earnings report date?
Assembly Biosciences’s upcoming earnings report date is Aug 12, 2026 which is in 70 days.
How were Assembly Biosciences’s earnings last quarter?
Assembly Biosciences released its earnings results on May 07, 2026. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.65 by $0.11.
Is Assembly Biosciences overvalued?
According to Wall Street analysts Assembly Biosciences’s price is currently Undervalued.
Does Assembly Biosciences pay dividends?
Assembly Biosciences does not currently pay dividends.
What is Assembly Biosciences’s EPS estimate?
Assembly Biosciences’s EPS estimate is -0.73.
How many shares outstanding does Assembly Biosciences have?
Assembly Biosciences has 19,251,210 shares outstanding.
What happened to Assembly Biosciences’s price movement after its last earnings report?
Assembly Biosciences reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.65. Following the earnings report the stock price went down -3.847%.
Which hedge fund is a major shareholder of Assembly Biosciences?
Currently, no hedge funds are holding shares in ASMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Assembly Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$44.33 (51.62% Upside)
$44.33 (51.62% Upside)
Hedge Fund Trend
Decreased
By 9.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.8%
Last 30 Days ▼ 5.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.70%
12-Months-Change
Fundamentals
Return on Equity
-4.21%
Trailing 12-Months
Asset Growth
137.85%
Trailing 12-Months
Company Description
Assembly Biosciences
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
ASMB Stock 12 Month Forecast
Average Price Target
$44.33
▲(51.62% Upside)
Technical Analysis
Benitec Biopharma
―
Annexon Biosciences
―
Quantum-Si
―
Vor Biopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
27.52% Insiders
4.03% Mutual Funds
52.97% Other Institutional Investors
12.76% Public Companies and
Individual Investors